| Research progress on prevention and treatment of adiponectin in diabetic cardiomyopathy |
| Click here to download the full text |
| Citation of this paper:WU Xia1△, WU Xue-ting2△, HUANG Lei-tao3, ZHOU Xue-liang1, TAO En-de4, LIU Ji-chun1*.Research progress on prevention and treatment of adiponectin in diabetic cardiomyopathy[J].Chinese Journal of Clinical Medicine,2019,26(1):145-150 |
| Hits: 1560 |
| Download times: 887 |
| Author Name | Affiliation | | WU Xia1△, WU Xue-ting2△, HUANG Lei-tao3, ZHOU Xue-liang1, TAO En-de4, LIU Ji-chun1* | 1.Department of Thoracic and Cardiovascular Surgery, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
2.Family Planning Service Station, Xiangcheng 466200, Henan, China
3.Department of Orthopedics, the Fourth Affiliated Hospital of Nanjing Medical University, Nanjing 210031, Jiangsu, China
4.Department of Cardiac Surgery, Wuhan Asia Heart Hospital, Wuhan 430022, Hubei, China |
|
| Abstract:Diabetic cardiomyopathy (DCM) is an independent ischemic heart disease that occurs on the basis of diabetes, excluding diseases originated from the heart itself. The pathogenesis of DCM is caused by multiple factors and is still not well elucidated. It involves the injury of cardiac myocytes, hyperglycemia, energy metabolism disorder, and cardiac microvascular disease. Adiponectin (APN) has been found to be able to reduce the level of glycemia and regulate blood lipids, and has anti-apoptotic, anti-inflammatory, and antioxidant properties, as also be able to prevent atherosclerosis, and has close relationship with the development of DCM. Therefore, this article describes and summarizes the role of adiponectin in DCM. |
| keywords:adiponectin diabetic cardiomyopathy oxidative stress apoptosis fibrosis |
| HTML View Full Text View/Add Comment Download reader |
|
|
|